

ASX ANNOUNCEMENT

14 April 2025

Change of Registered Office and Registry Address

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, advises that in accordance with ASX Listing Rules 3.14 and 3.15.1 and with effect from 14 April 2025, its registered office address and the address at which its register of securities is kept has moved to:

Liberty Place
Level 41
161 Castlereagh Street
Sydney NSW 2000

Other contact details are as follows:

Telephone	1300 554 474
Email	support@cm.mpms.mufg.com
Postal address	Locked Bag A14 Sydney South NSW 1235 Australia

Signed for and on behalf of Clarity



Robert Vickery
Company Secretary

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers in children and adults.

www.claritypharmaceuticals.com

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor

Executive Chairperson

ataylor@claritypharm.com

Catherine Strong

Investor/Media Relations

c.strong@morrrowsodali.com

+61 406 759 268